|
Revlimid
Hi Ulla,
I don´t know anything about Revlimid that they didn´t write in the EMEA paper but as far as I understand they found that AML transformation had been more commonly observed in patients who had not evidenced a cytogenic response to Revlimid treatment and who had frequently had limited exposure to this drug (page 48).
I don´t know if this means that patients that have a good response do not have an increased risk of AML. They have shown in another study that patiens with anemia (not low WBC:s and platelets) have the best response to Revlimid.
Kind regards
Birgitta-A
|